Chemed (NYSE:CHE – Get Free Report) issued an update on its FY 2024 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 23.300-23.700 for the period, compared to the consensus estimate of 23.520. The company issued revenue guidance of -. Chemed also updated its FY24 guidance to $23.30-23.70 EPS.
Chemed Price Performance
Shares of NYSE CHE traded down $14.19 during mid-day trading on Friday, hitting $559.15. The company had a trading volume of 84,373 shares, compared to its average volume of 79,687. Chemed has a 12 month low of $492.84 and a 12 month high of $654.62. The firm has a market cap of $8.45 billion, a P/E ratio of 30.86, a PEG ratio of 2.48 and a beta of 0.42. The business’s 50-day simple moving average is $623.76 and its 200-day simple moving average is $590.54.
Chemed (NYSE:CHE – Get Free Report) last released its quarterly earnings data on Wednesday, April 24th. The company reported $4.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). The firm had revenue of $589.23 million for the quarter, compared to the consensus estimate of $587.18 million. Chemed had a net margin of 12.36% and a return on equity of 31.69%. As a group, sell-side analysts predict that Chemed will post 21.99 EPS for the current year.
Chemed Announces Dividend
Wall Street Analyst Weigh In
A number of brokerages have commented on CHE. Royal Bank of Canada raised their price target on shares of Chemed from $604.00 to $712.00 and gave the stock an outperform rating in a research note on Monday, March 4th. Oppenheimer boosted their price target on Chemed from $625.00 to $650.00 and gave the company an outperform rating in a research note on Thursday, February 29th.
View Our Latest Stock Report on CHE
Insider Buying and Selling
In related news, EVP Spencer S. Lee sold 2,000 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now directly owns 20,760 shares in the company, valued at approximately $13,320,654. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Chemed news, EVP Spencer S. Lee sold 2,000 shares of Chemed stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total value of $1,283,300.00. Following the sale, the executive vice president now owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael D. Witzeman sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $643.14, for a total value of $1,704,321.00. Following the transaction, the chief financial officer now directly owns 2,882 shares of the company’s stock, valued at approximately $1,853,529.48. The disclosure for this sale can be found here. Insiders sold a total of 15,808 shares of company stock valued at $10,184,531 over the last three months. Company insiders own 3.32% of the company’s stock.
About Chemed
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.
Recommended Stories
- Five stocks we like better than Chemed
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks Leading the U.S. Agriculture Comeback
- How Investors Can Find the Best Cheap Dividend Stocks
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What are earnings reports?
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.